US2021395259A1PendingUtilityA1

Cdk inhibitors

78
Assignee: G1 THERAPEUTICS INCPriority: Oct 25, 2010Filed: Jan 20, 2021Published: Dec 23, 2021
Est. expiryOct 25, 2030(~4.2 yrs left)· nominal 20-yr term from priority
Inventors:Francis Xavier TavaresJay Copeland Strum
C07D 519/00C07D 487/20C07D 498/14A61K 31/527C07D 487/14A61K 31/499
78
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Compounds of Formulae I, II or III, and pharmaceutically acceptable salts thereof, are useful as CDK inhibitors.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A compound selected from: 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
     
     
         2 . The compound of  claim 1  selected from: 
       
         
           
           
               
               
           
         
       
     
     
         3 . The compound of  claim 2 , wherein the compound is: 
       
         
           
           
               
               
           
         
       
     
     
         4 . The compound of  claim 2 , wherein the compound is: 
       
         
           
           
               
               
           
         
       
     
     
         5 . The compound of  claim 2 , wherein the compound is:

Join the waitlist — get patent alerts

Track US2021395259A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.